MedTrace Logo

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

NCT00928174 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-11-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments for patients with androgen-insensitive prostate cancer.

Conditions

Interventions

DRUG

IV administration of fluorine-18 fluorocholine followed by PET/CT imaging

Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Queen's Medical Center

    lead OTHER

Principal Investigators

  • Sandi A Kwee, MD · The Queen's Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928174 on ClinicalTrials.gov